Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 19/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | NPC1 | O15118 | 3/20 | 0.74 |
| ▸ | RAB9A | P51151 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16554172 | 1.00 | SCD (1.00) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL16553868 | 1.00 | SCD (1.00) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL16553871 | 1.00 | SCD (1.00) | SCDKMT2AMEN1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL17909499 | 0.99 | SCD (0.98) | SCDKMT2AMEN1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL17909496 | 0.99 | SCD (0.98) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL16554178 | 0.91 | SCD (0.83) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL4912951 | 0.88 | SCD (1.00) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL16554160 | 0.86 | SCD (1.00) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL4917823 | 0.86 | SCD (0.87) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL31243 | 0.86 | SCD (1.00) | SCDKMT2AMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022093770-A1 | COMBINATION THERAPY WITH PI3K-AKT-MTOR INHIBITORS AND FERROPTOSIS INDUCING AGENTS TO TREAT CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-05-05 | — | — | WO | claimed |
| CN-119462655-A | Quinazolinone carboline compound, pharmaceutical composition and application thereof | 江南大学 | 2025-02-18 | — | — | CN | disclosed |
| US-11833144-B2 | Treating autoimmune disease | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-12-05 | — | — | US | disclosed |
| CN-113057955-B | Medicine for inhibiting stearoyl-CoA desaturase 1 | 江南大学 | 2023-03-24 | — | — | CN | disclosed |
| WO-2022093770-A1 | COMBINATION THERAPY WITH PI3K-AKT-MTOR INHIBITORS AND FERROPTOSIS INDUCING AGENTS TO TREAT CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20220062259-A1 | TREATING AUTOIMMUNE DISEASE | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062259-A1 | TREATING AUTOIMMUNE DISEASE | SSB, SCD, SERPINB1 | SCD 2/4885KMT2A 4169/4885MEN1 1104/4885 |
| US-11833144-B2 | Treating autoimmune disease | NR5A1, SSB, RBP4 | SCD 11/4885KMT2A 3628/4885MEN1 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.